DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Multiple myeloma remains incurable despite advances in immunotherapies like chimeric antigen receptor (CAR) T-cell therapy. This study investigates the role of metabolites and gut microbiota in clinical outcomes in patients treated with the humanized B-cell maturation antigen (BCMA)-directed CAR-T therapy ARI0002h. Stool metabolites, particularly succinate, were associated with CAR T-cell phenotypes and persistence in patients. In CAR T-cell culture, succinate supplementation enhanced CD4+ central memory phenotype and respiratory capacity. In a murine myeloma model, a succinate-enhancing diet significantly improved CAR T-cell persistence and showed a trend toward better tumor control. Furthermore, Acidaminococcaceae, Monoglobaceae, or Akkermansiaceae, along with specific metabolites, were associated with CAR T-cell clinical outcomes. These multimodal profiles were integrated into response models, including one that identified patients likely to achieve a complete response by days 100 and 180 after infusion. These findings suggest that metabolites and gut microbiota correlate with CAR T-cell therapy responses and can be a valuable tool for risk assessment., This work has been partially supported by grants from the Instituto de Salud Carlos III (cofunded by the European Union), Spanish Ministry of Health (FIS PI18/00775, PICI18/00012 ICI19/00025, PI19/00669, PI22/00647, and complementary grant for CONCORD-023), Fondo Europeo de Desarrollo Regional “una manera de hacer Europa” 2021SGR01292 (AGAUR; Generalitat de Catalunya), “La Caixa” Foundation (CP042702/LCF/PR/GN18/50310007), RICORS-TERAV network (RD21/0017/0009 and RD21/0017/0019), Red de Terapia Celular (RD16/0011/0005), Centro de Investigación Biomédica en Red de Cáncer (CB16/12/00369 and CB16/12/00489), Asociación Española Contra el Cáncer (LABAE21971FERN), and Fundació Bosch I Aymerich., Peer reviewed
Proyecto:
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII) PI18-00775
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI19-00669
,
ISCIII / Plan Estatal de Investigación Científica PI22-00647
DOI: http://hdl.handle.net/10261/406228, https://api.elsevier.com/content/abstract/scopus_id/105015202060
HANDLE: http://hdl.handle.net/10261/406228, https://api.elsevier.com/content/abstract/scopus_id/105015202060